Erasca Inc. Eyes $150 M Public Offering to Fuel Oncology R&D, Markets React Mixedly
Read how Erasca’s $150 M public offering could fuel precision oncology research amid mixed investor sentiment.
3 minutes to read
Erasca Inc
Erasca Inc.: Volatile Surge, Analyst Overweight and Conference Push
Explore Erasca Inc.’s volatile stock, analyst “overweight” support, and upcoming J.P. Morgan Healthcare Conference to gauge future upside and risks.
3 minutes to read
Erasca Inc. Secures 2043 Patent, Charts 2026 Phase‑1 Oncology Milestones, & Maintains 2028 Cash Runway
Read Erasca’s Q3 2025 results: patent win for KRAS therapy, 2026 Phase 1 plans, and a multi‑year cash runway—key insights for investors in precision oncology.
2 minutes to read
Erasca, Inc. Navigates Volatility with Focus on Precision Oncology Innovations
Erasca, Inc. is a clinical-stage precision oncology company dedicated to developing innovative cancer treatments through precision medicine, despite facing challenges and uncertainties in the healthcare industry.
2 minutes to read
Erasca Inc. Advances in Precision Oncology with FDA Clearance and Strategic Partnerships
Erasca, Inc. has made significant strategic moves, including FDA clearance of its new cancer drug ERAS-0015, and plans to seek partnerships for its phase 3 asset, positioning the company for continued growth in the precision oncology sector.
3 minutes to read